Alpha-therapy, in which alpha-particle-emitting radionuclides such as 227Th are delivered specifically to tumor tissues, is emerging as a novel strategy for targeted cancer therapy.
No one denies that fewer new drugs will be a consequence of the Medicare drug pricing provisions the Democrats are trying to push through the U.S. Congress ahead of the midterm election campaign season. Less attention has been paid to the negative impact on drug-device combinations and new diagnostics that accompany innovative treatments.
With data due later this summer from the phase II Pioneer trial testing Blueprint Medicines Corp.’s approved Ayvakit (avapritinib), many investor eyes are on the potential label expansion into indolent systemic mastocytosis – but the company has another potential ace in the hole with BLU-451, which targets EGFR exon 20 insertion mutations in non-small-cell lung cancer (NSCLC).
The FDA has cleared Jubilant Therapeutics' IND application for JBI-778, an oral, brain-penetrant and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, for the treatment of solid tumors with brain metastases and primary brain tumors, including high-grade glioma.
It has been previously demonstrated that MYCN amplification frequently occurs in high-risk neuroblastoma (NB), and it is correlated with an undifferentiated phenotype and poor prognosis.
Helios-Huaming BioPharma has synthesized new substituted salicylamide compounds acting as protein-arginine deiminase type-4 (PADI4) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis and ischemia-reperfusion injury, among other disorders.
Shanghai Hengrui Pharmaceutical and Jiangsu Hengrui Medicine have described cyclohexadiimide derivatives reported to be useful for the treatment of cancer and neurological disorders.
No one denies that fewer new drugs will be a consequence of the Medicare drug pricing provisions the Democrats are trying to push through the U.S. Congress ahead of the midterm election campaign season.
RSS
